{"id":"https://openalex.org/W2946676809","doi":"https://doi.org/10.1136/ejhpharm-2019-eahpconf.14","title":"1ISG-014 Rheumatoid arthritis: biological drugs pharmaceutilisation analysis in an italian district","display_name":"1ISG-014 Rheumatoid arthritis: biological drugs pharmaceutilisation analysis in an italian district","alternate_titles":[],"publication_year":2019,"publication_date":"2019-03-01","ids":{"openalex":"https://openalex.org/W2946676809","doi":"https://doi.org/10.1136/ejhpharm-2019-eahpconf.14","mag":"2946676809"},"language":"en","primary_location":{"id":"doi:10.1136/ejhpharm-2019-eahpconf.14","doi":"https://doi.org/10.1136/ejhpharm-2019-eahpconf.14","is_oa":true,"landing_page_url":"https://doi.org/10.1136/ejhpharm-2019-eahpconf.14","pdf_url":"https://ejhp.bmj.com/content/ejhpharm/26/Suppl_1/A7.1.full.pdf","source":{"id":"https://openalex.org/S3012707348","display_name":"European Journal of Hospital Pharmacy","issn_l":"2047-9956","issn":["2047-9956","2047-9964"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Section 1: Introductory Statements and Governance","raw_type":"proceedings-article"},"parent_works":[],"lineage":["https://openalex.org/W2946676809"],"child_works_count":0,"type":"conference-paper","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://ejhp.bmj.com/content/ejhpharm/26/Suppl_1/A7.1.full.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5018460402","display_name":"E Viglione","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210096652","display_name":"Ospedale di Rivoli","ror":"https://ror.org/00swfce58","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210096652"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"E Viglione","raw_affiliation_strings":["ASL TO3, Hospital Pharmacy, Rivoli, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ASL TO3, Hospital Pharmacy, Rivoli, Italy","institution_ids":["https://openalex.org/I4210096652"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102719471","display_name":"Marco Lecis","orcid":"https://orcid.org/0000-0002-9374-7343","observed_orcids":["https://orcid.org/0000-0002-9374-7343"]},"institutions":[{"id":"https://openalex.org/I4210096652","display_name":"Ospedale di Rivoli","ror":"https://ror.org/00swfce58","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210096652"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"M Lecis","raw_affiliation_strings":["ASL TO3, Hospital Pharmacy, Rivoli, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ASL TO3, Hospital Pharmacy, Rivoli, Italy","institution_ids":["https://openalex.org/I4210096652"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087342347","display_name":"S Strobino","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210096652","display_name":"Ospedale di Rivoli","ror":"https://ror.org/00swfce58","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210096652"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"S Strobino","raw_affiliation_strings":["ASL TO3, Hospital Pharmacy, Rivoli, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ASL TO3, Hospital Pharmacy, Rivoli, Italy","institution_ids":["https://openalex.org/I4210096652"]}]},{"author_position":"last","author":{"id":null,"display_name":"G Ceravolo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210096652","display_name":"Ospedale di Rivoli","ror":"https://ror.org/00swfce58","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210096652"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"G Ceravolo","raw_affiliation_strings":["ASL TO3, Hospital Pharmacy, Rivoli, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ASL TO3, Hospital Pharmacy, Rivoli, Italy","institution_ids":["https://openalex.org/I4210096652"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210096652"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"A7.1","last_page":"A7"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.9901999831199646,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.9901999831199646,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.0017000000225380063,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.0017000000225380063,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rheumatoid-arthritis","display_name":"rheumatoid arthritis","score":1.0},{"id":"https://openalex.org/keywords/biological-drugs","display_name":"biological drugs","score":0.8939999938011169},{"id":"https://openalex.org/keywords/defined-daily-doses","display_name":"defined daily doses","score":0.7900000214576721},{"id":"https://openalex.org/keywords/immunosuppressive-drugs","display_name":"immunosuppressants","score":0.8080000281333923},{"id":"https://openalex.org/keywords/secukinumab","display_name":"secukinumab","score":0.9440000057220459},{"id":"https://openalex.org/keywords/tocilizumab","display_name":"tocilizumab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/etanercept","display_name":"etanercept","score":0.906000018119812},{"id":"https://openalex.org/keywords/infliximab","display_name":"infliximab","score":1.0},{"id":"https://openalex.org/keywords/mycophenolate","display_name":"mycophenolate","score":0.9300000071525574},{"id":"https://openalex.org/keywords/prescribing-trends","display_name":"prescribing trends","score":0.7260000109672546},{"id":"https://openalex.org/keywords/prescribing-appropriateness","display_name":"prescribing appropriateness","score":0.6600000262260437}],"concepts":[{"id":"https://openalex.org/C2777575956","wikidata":"https://www.wikidata.org/wiki/Q187255","display_name":"Rheumatoid arthritis","level":2,"score":0.8955538272857666},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.878357470035553},{"id":"https://openalex.org/C2426938","wikidata":"https://www.wikidata.org/wiki/Q3355478","display_name":"Medical prescription","level":2,"score":0.7467741370201111},{"id":"https://openalex.org/C2777226972","wikidata":"https://www.wikidata.org/wiki/Q415343","display_name":"Etanercept","level":3,"score":0.7164610624313354},{"id":"https://openalex.org/C2777138892","wikidata":"https://www.wikidata.org/wiki/Q415264","display_name":"Infliximab","level":3,"score":0.6222203969955444},{"id":"https://openalex.org/C2777178219","wikidata":"https://www.wikidata.org/wiki/Q425154","display_name":"Tocilizumab","level":3,"score":0.5383888483047485},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4400140345096588},{"id":"https://openalex.org/C59491497","wikidata":"https://www.wikidata.org/wiki/Q864715","display_name":"Biosimilar","level":2,"score":0.4361899793148041},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.29425084590911865},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.23256725072860718}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1136/ejhpharm-2019-eahpconf.14","doi":"https://doi.org/10.1136/ejhpharm-2019-eahpconf.14","is_oa":true,"landing_page_url":"https://doi.org/10.1136/ejhpharm-2019-eahpconf.14","pdf_url":"https://ejhp.bmj.com/content/ejhpharm/26/Suppl_1/A7.1.full.pdf","source":{"id":"https://openalex.org/S3012707348","display_name":"European Journal of Hospital Pharmacy","issn_l":"2047-9956","issn":["2047-9956","2047-9964"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Section 1: Introductory Statements and Governance","raw_type":"proceedings-article"}],"best_oa_location":{"id":"doi:10.1136/ejhpharm-2019-eahpconf.14","doi":"https://doi.org/10.1136/ejhpharm-2019-eahpconf.14","is_oa":true,"landing_page_url":"https://doi.org/10.1136/ejhpharm-2019-eahpconf.14","pdf_url":"https://ejhp.bmj.com/content/ejhpharm/26/Suppl_1/A7.1.full.pdf","source":{"id":"https://openalex.org/S3012707348","display_name":"European Journal of Hospital Pharmacy","issn_l":"2047-9956","issn":["2047-9956","2047-9964"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Section 1: Introductory Statements and Governance","raw_type":"proceedings-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9763000011444092,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2946676809.pdf","grobid_xml":"https://content.openalex.org/works/W2946676809.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2620454779","https://openalex.org/W2937044336","https://openalex.org/W2474035472","https://openalex.org/W4409867791","https://openalex.org/W2105585974","https://openalex.org/W4399976728","https://openalex.org/W4303090620","https://openalex.org/W3155768314","https://openalex.org/W4402939975","https://openalex.org/W1709917879"],"abstract_inverted_index":{"Background":[0],"Rheumatoid":[1],"arthritis":[2,32,104,151],"is":[3,37,45,50,270,288],"a":[4,19,84,254],"chronic":[5],"systemic":[6],"inflammatory":[7],"disease":[8],"that":[9,49,174,248],"concerns,":[10],"above":[11],"all,":[12],"the":[13,26,30,35,108,115,119,128,133,161,200,207,221,235,274,281],"industrialised":[14],"countries":[15],"and":[16,40,42,75,77,88,132,170,197,202,232,237,280,295,306,311],"it":[17,244],"has":[18,252],"high":[20],"rate":[21],"of":[22,59,130,220,277,283,293,323],"development.":[23],"According":[24],"to":[25,47,82,107,210,215,260,273,297,303,309],"World":[27],"Health":[28],"Organization,":[29],"rheumatoid":[31,103,150,265],"prevalence":[33],"in":[34,43,63,80,102,114,157,199,204,206,228,234,249,257,301],"world":[36],"between":[38,66],"0.3%":[39],"1%":[41],"Italy":[44],"equivalent":[46],"0.33/100,":[48],"about":[51],"2":[52],"00":[53,72],"000":[54,73],"patients.":[55],"Purpose":[56],"The":[57,267],"aim":[58],"this":[60,229,242],"work":[61],"consists":[62],"comparing":[64],"prescriptions":[65,148],"an":[67,125,141],"Italian":[68,126,142],"district,":[69,127,144],"including":[70],"6":[71],"citizens,":[74],"regional":[76,169],"national":[78,171,238],"prescriptions,":[79],"order":[81,302],"make":[83],"pharmaceutilisation":[85],"analysis.":[86],"Material":[87],"methods":[89],"Immunosuppressive":[90,212],"drugs":[91,213],"have":[92,136,152,175],"been":[93,137,153,253],"analysed":[94],"(Anatomical":[95],"Therapeutic":[96],"Chemical":[97],"(ATC)":[98],"classification:":[99],"L04),":[100],"employed":[101],"therapy,":[105],"according":[106],"defined":[109],"daily":[110],"dose":[111],"(DDD),":[112],"divided":[113],"ATC":[116,216,261],"classification,":[117],"concerning":[118,124,146],"two-year":[120],"period":[121],"2016/2017.":[122],"Prescriptions":[123],"region":[129,236],"belonging":[131,214,259],"whole":[134,222],"nation":[135],"compared.":[138],"Results":[139],"In":[140,187,224],"north":[143],"DDDs":[145,173,192,226],"immunosuppressive":[147],"for":[149,264,290],"increased":[154,176,194,227],"by":[155],"14.6%":[156],"2017":[158,250],"compared":[159,209],"with":[160],"previous":[162],"year,":[163],"however":[164],"they":[165],"are":[166,193],"being":[167],"on":[168],"average.":[172],"more":[177],"concern":[178],"secukinumab":[179],"(+1135.3%)":[180],"and,":[181],"in,":[182],"less":[183],"quantity,":[184],"tocilizumab":[185],"(+59.6%).":[186],"2017,":[188,225],"every":[189],"molecules":[190,258,279],"considered":[191],"except":[195],"etanercept":[196],"infliximab":[198],"region,":[201],"mycophenolate":[203],"general":[205],"nation,":[208],"2016.":[211],"L04":[217,262],"totals":[218],"2.2%":[219],"DDD.":[223],"district":[230],"(+14.6%)":[231],"also":[233],"territory.":[239],"Conclusion":[240],"From":[241],"analysis,":[243],"can":[245],"be":[246],"said":[247],"there":[251],"DDD":[255],"increase":[256],"prescribed":[263],"arthritis.":[266],"pharmaceutical":[268],"market":[269],"booming":[271],"thanks":[272],"frequent":[275],"introduction":[276],"new":[278,284],"updating":[282],"therapeutic":[285],"indications.":[286],"It":[287],"necessary":[289],"continuous":[291],"training":[292],"prescriptors":[294],"pharmacists":[296],"ensure":[298],"prescriptive":[299],"appropriateness":[300],"deliver":[304],"suitable":[305],"effective":[307],"therapy":[308],"patients,":[310],"economic":[312],"sustainability.":[313],"References":[314],"and/or":[315],"acknowledgements":[316],"Biosimilar":[317],"position":[318],"paper":[319],"AIFA.":[320],"No":[321],"conflict":[322],"interest.":[324]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2946676809","counts_by_year":[],"updated_date":"2026-11-02T09:45:03.842371","created_date":"2019-05-29T00:00:00"}
